{"entity":{"id":"nct05754853","kind":"trial","name":"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer","aka":[],"tldr":"A phase 3 trial testing MRG002 in bladder & urothelial cancer, now recruiting.","summary":"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT05754853, led by Shanghai Miracogen, and recruiting on the registry. Official title: An Open-label, Randomised, Multi-centre, Phase III Clinical Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelial Cancer Previously Treated With Platinum-based Chemotherapy and PD-1/PD-L1 Inhibitors. Planned enrolment is 290 participants (estimated). The study started in 2023-04-06 and primary completion is expected in 2025-10. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05754853","url":"https://clinicaltrials.gov/study/NCT05754853"}],"tags":["ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["mrg002"],"companies":["shanghai-miracogen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05754853","phase":"3","setting":"An Open-label, Randomized, Multi-center, Phase III Clinical Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelial Cancer Previously Treated With Platinum-based Chemotherapy and PD-1/PD-L1 Inhibitors","sponsor":"Shanghai Miracogen","participation":[{"nct":"NCT05754853","source":"https://clinicaltrials.gov/study/NCT05754853","fetchedAt":"2026-10-07T16:53:54.339Z","studySha256":"e872a453f622ee7013c695f6ea7a011edace911d83359da02830b6949a9e084e","overallStatus":"RECRUITING","lastUpdatePosted":"2023-04-13","leadSponsor":"Shanghai Miracogen Inc.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":290,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2023-04-06","startedType":"estimated","enrolled":290,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05754853/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"drug":[{"id":"mrg002","kind":"drug","name":"MRG002","route":"/drugs/mrg002/"}],"company":[{"id":"shanghai-miracogen","kind":"company","name":"Shanghai Miracogen","route":"/companies/shanghai-miracogen/"}]}}